Spark Therapeutics, Inc. (ONCE) Given a $101.00 Price Target at SunTrust Banks, Inc.

SunTrust Banks, Inc. set a $101.00 price target on Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research report released on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also issued reports on ONCE. Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a $111.00 price target on shares of Spark Therapeutics in a report on Friday, October 6th. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the stock a buy rating in a report on Tuesday, October 10th. Cowen and Company reissued a buy rating and issued a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial, Inc. assumed coverage on shares of Spark Therapeutics in a report on Thursday, October 12th. They issued an outperform rating and a $96.00 price target on the stock. Finally, Barclays PLC raised their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an overweight rating in a report on Friday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. Spark Therapeutics presently has a consensus rating of Buy and a consensus target price of $90.47.

Shares of Spark Therapeutics (NASDAQ ONCE) opened at 85.53 on Monday. The company’s market cap is $2.67 billion. The firm’s 50-day moving average is $85.85 and its 200-day moving average is $85.85. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. Spark Therapeutics’s revenue was up 14.7% on a year-over-year basis. During the same period last year, the business earned ($1.04) EPS. On average, equities research analysts predict that Spark Therapeutics will post ($7.59) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. (ONCE) Given a $101.00 Price Target at SunTrust Banks, Inc.” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://ledgergazette.com/2017/10/17/spark-therapeutics-inc-once-given-a-101-00-price-target-at-suntrust-banks-inc.html.

In related news, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $72.53, for a total transaction of $725,300.00. Following the completion of the transaction, the insider now directly owns 220,000 shares of the company’s stock, valued at approximately $15,956,600. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last ninety days. Insiders own 7.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics during the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA lifted its position in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares during the period. Pacad Investment Ltd. lifted its position in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in Spark Ther

A number of other brokerages have also issued reports on ONCE. Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a $111.00 price target on shares of Spark Therapeutics in a report on Friday, October 6th. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the stock a buy rating in a report on Tuesday, October 10th. Cowen and Company reissued a buy rating and issued a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial, Inc. assumed coverage on shares of Spark Therapeutics in a report on Thursday, October 12th. They issued an outperform rating and a $96.00 price target on the stock. Finally, Barclays PLC raised their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an overweight rating in a report on Friday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. Spark Therapeutics presently has a consensus rating of Buy and a consensus target price of $90.47.

Shares of Spark Therapeutics (NASDAQ ONCE) opened at 85.53 on Monday. The company’s market cap is $2.67 billion. The firm’s 50-day moving average is $85.85 and its 200-day moving average is $85.85. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. Spark Therapeutics’s revenue was up 14.7% on a year-over-year basis. During the same period last year, the business earned ($1.04) EPS. On average, equities research analysts predict that Spark Therapeutics will post ($7.59) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. (ONCE) Given a $101.00 Price Target at SunTrust Banks, Inc.” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://ledgergazette.com/2017/10/17/spark-therapeutics-inc-once-given-a-101-00-price-target-at-suntrust-banks-inc.html.

In related news, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $72.53, for a total transaction of $725,300.00. Following the completion of the transaction, the insider now directly owns 220,000 shares of the company’s stock, valued at approximately $15,956,600. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last ninety days. Insiders own 7.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics during the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA lifted its position in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares during the period. Pacad Investment Ltd. lifted its position in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in Spark Therapeutics during the 1st quarter valued at about $227,000. 77.84% of the stock is owned by institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply